1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Abstract

Concerns about the safety of PD-1/PD-L1 blockade in human immunodeficiency virus type 1 (HIV-1)-infected individuals have led to the exclusion of these patients from clinical trials on cancer immunotherapies. In order to evaluate the feasibility of durvalumab treatment in HIV-patients with advanced cancer we conducted the DURVAST study, a non-randomized, open-label, phase 2 clinical trial that demonstrated clinical activity with acceptable toxicity rates in this setting. Here we present the long-term clinical outcomes of the study.